The characterization of the metabolic deregulations that distinguish cancer phenotypes, and which might be effectively targeted by ad-hoc therapeutic strategies, is a key open challenge. To this end, we here introduce MaREA (Metabolic Reaction Enrichment Analysis), a computational pipeline that processes cross-sectional RNAseq data to identify the metabolic reactions that are significantly up-/ down-regulated in different sample subgroups. MaREA relies on the definition of a Reaction Activity Score, computed as a function of the expression level of genes encoding for reaction enzymes, which can also be used as an effective metrics to cluster samples into distinct metabolic subgroups. MaREA finally allows to visualize the results in a graphical form directly on metabolic maps. We apply MaREA to distinct cancer datasets and we show that it can produce useful information and new experimental hypotheses on metabolic deregulation of cancer cells, also allowing to stratify patients in metabolic clusters with significantly different survival expectancy.
Introduction
The heterogeneity of cancer genotypes and phenotypes hinders the identification of targets for effective treatments and is a major cause of tumor relapse. Therefore, it is common practice to statistically compare the gene expression of patient cohorts, based on clinical observations and/ or molecular features, in order to understand how the hallmarks of cancer can be (alternatively) achieved in terms of gene expression regulation. An hallmark in particular is of interest for cancer treatment: the metabolic reprogramming of cancer cells [1, 2] .
Current research on cancer metabolism typically relies on genome-wide reconstructions of human metabolic networks [3] , such as HMR [4] and Recon 2.2 [5] . These models include most metabolic reactions that may occur in a generic cell. Different strategies are used to extract relevant sub-models, e.g., the active metabolic networks in a given cell or tissue, in order to investigate its specific molecular features, possibly identifying relevant biomarkers and therapeutic targets. Current methodologies to this end employ transcriptome, proteome or even metabolome data (as reviewed in [6, 7, 8] ). Such models are typically used in Flux Balance Analysis (FBA), a technique that exploits linear programming to compute the flux through each reaction under a steady state assumption, and which requires further constraints on incoming nutrients and outgoing products (i.e., exchange reactions) [9] . Yet, retrieving such information might be hard, as the simultaneous presence of metabolic measurements and transcriptomic data on same patient are rarely available in public databases, such as, e.g., the The Cancer Genome Atlas (TCGA) [10] We here propose MaREA (Metabolic Reaction Enrichment Analysis) ( Figure   1 ) as an alternative computational approach to investigate cancer metabolism, when data on metabolic measurements are not available, which explicitly focuses on transcriptional regulation of metabolic reactions.
MaREA processes RNAseq data, as one can retrieve from publicly available databases such as TCGA [10] . For each reaction of a given metabolic network, MaREA computes a Reaction Activity Score (RAS), which describes the extent of its activity in a given condition, as a function of the expression level of the genes encoding for the subunits and/ or the isoforms of the enzyme catalyzing such reaction. This score provides a more refined information than the mere list of genes associated to a reaction, without requiring to set any arbitrary threshold, nor to binarize data (gene present or absent), as required by other approaches [11] . Besides, MaREA does not perform FBA simulation, but only employs the RAS as a static representation of the metabolic behavior of a given sample, which can be then used to compare different sample sets (e.g., different patient cohorts, or control vs. tumor), identifying over (or under) expressed reactions.
Our approach markedly differs from that of Gene Set Enrichment Analysis (GSEA), which aims at characterizing the sets of up-or down-regulated genes in different phenotypes [12] . The typical outcome of GSEA analysis provides generic indications on the deregulated functions of a cell, or on specific functional behaviors when focusing on particular gene sets, derived, for instance, from the Reactome pathway database [13] . Nevertheless, the enriched sets are mere list of genes involved in comprehensive metabolic pathways (as, e.g., DNA replication), failing to provide details on which specific metabolic routes of a large pathway are favored in a given condition. In particular, metabolic functions can be alternatively achieved by metabolizing different nutrients and/ or by following different catabolic and anabolic routes, in a complex and largely undeciphered interplay. For this reason, simply knowing weather a certain function is up or down-regulated might not be sufficient to shed light on how such function might be achieved in distinct cancer phenotypes. In this regard, MaREA can provide a much finer resolution to the analysis and the enrichment of metabolic reactions in distinct experimental conditions. More recent approaches aim at building sets of genes to be enriched according to the information included in genome-wide metabolic networks.
Specifically, metabolic reporter analyses try to provide knowledge about variations in metabolite concentrations, starting from sets of genes classified according to the metabolite they associate with [14] . However, such methods do not provide information about which reactions are up-or down-regulated, and thus hinders the identification of putative targets for cancer treatment.
MaREA allows to overcome the limitations of current methods, providing a fine instrument for cancer metabolism investigation based on simple assumptions and easily-accessible transcriptomic data. Similar in spirit to the recently introduced PARADIGM approach (PAthway Recognition Algorithm using Data Integration on Genomic Models [15] ), MaREA extracts a feature (the RAS) for each sample. However PARADIGM relies on the integrating of data from multiple sources and requires curated pathway interactions among genes, hence both the input data and final objective are significantly different.
Importantly, the features extracted by MaREA can be used to stratify samples in an unsupervised manner (Metabolic Feature Extraction). Such stratification might provide relevant prognostic indications, as shown in the case studies in Section 2. Distinct approaches make use, for instance, of the information on enriched pathways [16] or of that on mutational profiles [17, 18] to classify cancer samples and subtypes.
Summarizing, MaREA can be used to: i) rank the reactions according to the variation in their activity observed between different phenotypes and/ or experimental conditions; ii) enrich the map of human metabolic routes with the variation observed in the RAS of each reaction, providing a clear visualization of how deregulated paths are interconnected; iii) efficiently stratify samples according to their metabolic activity, hence providing a new (unsupervised) clustering tool, with testable clinical relevance, which can be assessed, e.g., via standard survival analyses.
As a proof of principle, we applied MaREA to data publicly available in the TCGA database [10] . We computed the RASs by taking into account either all the Gene-Protein Rules (GPRs) included in the genome wide-model Recon 2.2 [5] or a manually curated subset of it, corresponding to the model of central carbon metabolism previously used in [19, 20] . We identified and visualized the enriched metabolic reactions between normal and cancer biopsies obtained from breast cancer patients (TCGA-BRCA dataset [21] ). Furthermore, we used the RASs to stratify breast cancer patients in distinct metabolic clusters, and performed standard survival analysis, which highlighted statistically significant prognostic predictions. MaREA takes as input a n sample × m genes matrix T which includes the normalized read count of each gene from a given cross-sectional RNAseq dataset. (B) MaREA can use different input metabolic reaction networks, e.g., the genome-wide Model, or any subset of it. (C) A Reaction Activity Score (RAS) is defined for any reaction r in the input network and any sample, by distinguishing the case of reactions involving enzymes composed by different subunits -in this case the RAS is computed as the minimum of the transcript level of the genes encoding the subunits -, and that of reaction catalyzed by different enzyme isoforms -in this case the RAS is computed as the sum of the transcript level of the genes encoding the isoforms. (D) Given two distinct subsets T A and T B of the original dataset, the RASs of a given reaction in the two cases are compared and if the p-value of the Kolmogorov-Smirnov test is significant (< 0.05) and the log2 fold-change is larger than 0.263, that reaction will be enriched in the final graph as up-or down-regulated. Accordingly, a reaction ranking can be provided. (E) MaREA can stratify patients by employing the RAS as metrics on standard clustering methods, e.g., k-means. Survival analyses, such as log-rank test on Kaplan-Meier curves, can finally provide a prognostic validation of the clusters (notice that the image is intended for explanatory purpose only and does not reproduce any real case study).
Materials and Methods
Input. MaREA takes as input any RNAseq dataset in the form of a n × m matrix T , where n is the number of genes and m is the number of samples of the considered cohort (see Figure 1 MaREA then filters T according to a specific input reaction network N , e.g., the genome-wide metabolic network [5] or any possible subset of it (see Section 2). In particular, we define the set of reactions as R = {r ∈ N }. Therefore, T is filtered by retaining only the rows corresponding to genes that are associated to enzymes involved in the reactions included in R (see Gene-protein rules are logical formulas that describe how gene products concur to catalyze a given reaction. Such formulas include AND and OR logical operators. AND rules are employed when distinct genes encode different subunits of the same enzyme, i.e., all the subunits are necessary for the reaction to occur. OR rules describe the scenario in which distinct genes encode isoforms of the same enzyme, i.e., either isoform is sufficient to catalyze the reaction.
For example the succinate-Coenzyme A ligase enzyme is formed by the subunits alpha (gene SUCLG1) and beta gene (SUCLG2) and catalyzes the reaction P i + succinyl-CoA + GDP ↔ CoA + succinate + GT P . The geneenzyme rule for this reaction is therefore: SUCLG1 AND SUCLG2. Conversely, ACACA and ACACB are respectively fully functional enzyme for the reaction acetyl-coenzyme A ligase carboxylase, thus the rule is ACACA OR ACACB. Such logical operators can of course be combined to depict multi-protein catalytic complexes or more complex situations involving both subunits and isoforms. For instance, ribonucleotide reductase is formed by two subunits: the catalytic (M1) and the regulatory one. The latter exists in two isoforms (M2 and M2B). The rule for this enzyme will therefore be RRM1 AND (RRM2 OR RRM2B).
Reaction Activity Score (RAS).
To avoid the definition of arbitrary thresholds on the transcript level, we do not resolve the logical expressions in a Boolean fashion, but we define a Reaction Activity Score (RAS), for each sample j = 1, . . . , m, and each reaction r ∈ R (see Figure 1 -C). In order to compute the RAS we distinguish:
• Reactions with AND operator (i.e., enzyme subunits).
where A r is the set of genes that encode the subunits of the enzyme catalyzing reaction r.
• Reactions with OR operator (i.e., enzyme isoforms).
where O r is the set of genes that encode isoforms of the enzyme that catalyzes reaction r.
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In case of composite reactions, we respect the standard precedence of the two operators. The final output is therefore a |R| × m matrix M , where each element M r,j is the RAS computed for reaction r in sample j.
The intuition underneath the introduction of the RAS is that enzyme isoforms contribute additively to the overall activity of a given reaction, whereas enzyme subunits limit its activity, by requiring all the components to be present for the reaction to occur.
Clearly, we are here adopting a deeply simplified approach to reaction network modeling, by neglecting, for instance, the great heterogeneity of reaction kinetic constants and protein binding affinities, of translation rates, and any possible post-transcriptional regulation effect that might occur within a cell. In this regard, an optimal choice would be to weigh all the reactions according to such quantities, yet direct measurements or robust estimates are very rarely available, especially for genome-wide models. Therefore, on first approximation, we here assume that all enzyme isoforms and subunits contribute uniformly to the reaction activity of a given reaction, as we expect that this choice does not affect the up-/ down-regulation interplay observed at the network level. MaREA then uses the significant RAS fold-changes to: i) determine a ranking of the most relevant up-and down-regulated reactions in the two sets,
ii) map such quantities over the input metabolic network N , by respectively coloring in red/ blue the up-/ down-regulated reactions, and by setting the edge thickness as proportional to the RAS fold-change. The reactions that will either display non-significant p-value or a RAS fold-change below the threshold will not be included in the ranking and will be marked in gray color on the metabolic network.
RAS-based sample stratification. Another major advantage of our approach is that it is possible to employ the RAS as an efficient metric to identify sample subgroups (or clusters) that share similar metabolic properties (see Figure   10 1-E). In particular, we here implemented a k-means clustering [22] which use the RASs of all reactions r ∈ R to identify sample clusters with distinct metabolic behaviours. Clusters can be compared by means of the reaction enrichment procedure described above, by ranking the significantly different reactions in the distinct clusters and visualizing the RAS fold-changes on the input network. Above all, clusters can also be tested via standard survival analysis, such as the log-rank test on Kaplan-Meier curves (when data is available), hence providing an important orthogonal validation of the clustering results with clinical relevance. In Section 2 we show how clustering on
RASs indeed can produce significant prognostic predictions. Dataset. We applied the MaREA pipeline to the breast cancer dataset (TCGA-BRCA) published in [21] , which also includes healthy/ control samples. We downloaded the dataset via the cBioPortal [28] (case study id: brca tcga pub2015).
This dataset includes the expression profile (RNA Seq V2 RSEM) of biopsies taken from 817 patients. For 105 of them, the expression profile of the normal tissue is also included. Because the TCGA-BRCA dataset identifies genes with Entrez IDs, we automatically converted them into HGNC IDs.
We found a correspondence for 1654 (379) genes over the 1673 (390) included in the genome-wide metabolic model. Although we neglected missing genes in the computation of the RASs, we were still able to compute a RAS for each reaction associated with a GPR.
Results

Breast Cancer vs. Normal
In order to evaluate the goodness of MaREA results, we first applied it to a largely characterized case-study: the comparison of cancer and normal metabolism. As long as ATP production is concerned, the interpretation of the situation portrayed by MaREA is, as expected, less straightforward. Cancer cells are believed to rely more on fermentation of glucose to lactate rather than on oxidation of glucose in the mitochondria (inner box of the map in In particular, up regulation of NADPH-dependent isocitrate dehydrogenase, which catalyzes the reductive carboxylation of -ketoglutarate (AKG) to isocitrate, may be linked with the mutations often reported for this enzyme in breast and other cancer types [30] . It has been suggested that this enzyme may support reductive glutamine metabolism in cancer and a branched TCA cycle flux mode [31] . Enhanced utilization of glutamine is indeed another hallmark of cancer cells [1, 2] . Accordingly, intake of glutamine is reported to be up regulated by MAREA.
The agreement of the results in Figure 2 with the obvious traits of cancer metabolism supports the reliability of our approach, which might shed light on less established traits. Deregulations of breast cancer metabolism identified by the approach, which may be worth of note are, among others: 1) deregulation of beta-oxidation of palmitate; 2) upregulation of folate metabolism; 3) deregulation of Phosphoenolpyruvate carboxykinase, which converts oxaloacetate (OAA) into phosphoenolpyruvate (PEP).
Reaction ranking. After filtering out the reactions whose activity does not differ between cancer and normal samples, MaREA allows to rank the re-maining reactions according to the extent of their up-or down-regulation.
Supplementary Table S1 report, for each reaction included in the genomewide model: the log fold change, the reaction formula, the pathway in which the reaction is involved and a description of its role. As genome-wide models include several reactions that are associated with the very same GPRs, typically involving transporters/enzymes with low substrate specificity, in Figure   2 we report the top 10 deregulated reactions with different GPRs. thus could play a role in the initiation of breast cancer [36] . Moreover, this enzyme can metabolize clinically important drugs, such as the tamoxifen [37] , which represents the most widely used hormonal therapy for breast cancer, and the coumarin [38, 39] , whose metabolisms have been proven to produce some metabolites having estrogenic and cytotoxic activities.
Comparison with GSEA results. The GSEA and MaREA approaches are not directly comparable, as they present several differences in goals, input data, parameters, variables and outputs. For instance, MAREA computes an individual activity score for each sample, whereas GSEA only considers expression fold-changes between pairs of experimental conditions. In order to provide an overview of how the information produced by the two complementary approaches may differ, without the ambition of claiming which approach should be preferred, we disregarded the addition multiple test correction (FDR) used by GSEA, and we considered the gene-sets that pass the nominal p-value test, with the same threshold used in MAREA standard settings (i.e., p=0.05). We did not set any threshold on the minimum size of gene-sets.
To run GSEA we used two kind of gene sets: 1) curated gene sets based on REACTOME, as directly provided by the GSEA tool; 2) gene-sets recon-structed by us, which correspond to the genes associated to each reaction in the genome-wide model and which are provided in gmt format (GSEA compliant) in Supplementary File S2. The former kind of gene-sets represent a typical application of GSEA to gene-sets involved in broad metabolic functions; whereas the second type is directly comparable to the sets used Taken together, these results indicate that MaREA provides a more complete and refined portray of metabolic deregulations. Moreover, as opposed to GSEA, MaREA computes an independent score for each sample (the RAS), which can be used to cluster samples in an unsupervised fashion. We illustrate such application of MaREA in the next section.
Metabolic Subgroups of Breast Cancer
In order to stratify samples by employing the RAS as clustering metrics, we performed k-means clustering with different input k ∈ {1, 2, . . . , 9} on the normalized RASs 1 of the reactions included in the HMRcore model. We performed n = 100 bootstrap iterations, with random centroid assignments, selecting as optimal the clustering run displaying the maximum inter-cluster distance. We then tested the resulting sample clusters against the survival probability (as retrieved from clinical data in the original dataset [21] ), via log-rank test on Kaplan-Meier curves. Interestingly, we found statistically significant overall survival curves (p < 0.05) for k = 2, k = 3, and k = 9 (significant results with respect to diseasefree and progression-free survival curves were observed as well, results not shown here).
In Figure 3 This result would first suggest that there exist a detectable metabolic signature of Basal-like cancer samples, and this is, to the best of our knowledge, a novel result, worth of further investigations. Besides, the mixed composition of Subgroups 1 and 2 may suggest that the differences observed at the metabolic level indeed translate into distinct survival probabilities, which standard classification may fail to capture.
More in detail, by looking at the reactions significantly up-/ down-regulated with respect to the case Subgroup 1 (best prognosis) vs. Subgroup 3 (worst prognosis) portrayed in Figure 3 for the core model -and in Supplementary Figure S2 and Table S2 for the genome-wide model -one can see that many reactions that are enriched in cancer against normal are also enriched in worst against best prognosis, including glycolysis, nucleotide synthesis and serine metabolism. Remarkably some metabolic pathways that are not significantly deregulated in cancer are significantly up regulated in the worse prognosis subgroup, with particular regard to palmitate biosynthesis.
Conclusions
We have here introduced MaREA, a computational pipeline that processes trascriptome profiles to produce usable information on metabolic reaction activities in different sample subgroups or experimental conditions. This is We remark that the final quality of MaREA's results deeply depends on the correctness of the gene-protein rules. We provided a curated version of the core model, but we automatically derived such rules from Recon 2.2 for the genome-wide analysis, thus our results might be improved via a more refined manual curation.
Even though we have here showed an application of MaREA to cancer patients, we remark that the approach can be used to compare any pair of conditions described by RNA-seq data samples (as, e.g., wild type vs. mutant organism). In the next future, we plan to release an user-friendly tool, which may be integrated within the Galaxy platform [41] , to leverage 24 the application of MaREA to any case study.
